SA author Austrolib provides a run-through of cancer vaccines from the "underwhelming to the...
SA author Austrolib provides a run-through of cancer vaccines from the "underwhelming to the exciting." The latter includes OncoVEX from Amgen (AMGN), which would be a buy if it weren't "skirting its all-time highs of $89 a share." Even more interesting are DCVax-L (brain) and DCVax-Direct (inoperable tumors) from Northwest Biotherapeutics (NWBO.OB). The problem is that Northwest has little cash and lots of debt notes.
From other sites
at Nasdaq.com (Thu, 3:17PM)
at Zacks.com (Thu, 9:30AM)
at Zacks.com (Mon, 6:12PM)
at 4-traders.com (Mon, 9:15AM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs